Human Vγ9Vδ2 T cells are attractive candidates for
cancer immunotherapy due to their potent capacity for
tumor recognition and cytolysis of many
tumor cell types. However, efforts to deploy clinical strategies for Vγ9Vδ2 T cell
cancer therapy are hampered by insufficient potency. We are pursuing an alternate strategy of modifying
tumors to increase the capacity for Vγ9Vδ2 T cell activation, as a means for strengthening the anti-
tumor response by resident or ex vivo manufactured Vγ9Vδ2 T cells. Vγ9Vδ2 T cells are activated in vitro by non-peptidic
antigens including isopentenyl pyrophosphate (
IPP), a substrate of
farnesyl diphosphate synthase (FDPS) in the pathway for biosynthesis of
isoprenoids. In an effort to improve in vivo potency of Vγ9Vδ2 T cells, we reduced FDPS expression in
tumor cells using a lentivirus vector encoding a
short-hairpin RNA that targets FDPS
mRNA (LV-shFDPS). Prostate (PC3) or
hepatocellular carcinoma (Huh-7) cells transduced with LV-shFDPS induced Vγ9Vδ2 T cell stimulation in vitro, resulting in increased
cytokine expression and
tumor cell cytotoxicity. Immune deficient mice implanted with LV-shFDPS transduced
tumor cells showed dramatic responses to
intraperitoneal injection of Vγ9Vδ2 T cells with strong suppression of
tumor growth. In vivo potency was increased by transducing
tumor cells with a vector expressing both shFDPS and human
IL-2.
Tumor suppression by Vγ9Vδ2 T cells was dose-dependent with greater effects observed in mice injected with 100% LV-shFDPS transduced cells compared to mice injected with a mixture of 50% LV-shFDPS transduced cells and 50% control (no vector)
tumor cells. Delivery of LV-shFDPS by intratumoral injection was insufficient to knockdown FDPS in the majority of
tumor cells, resulting in insignificant
tumor suppression by Vγ9Vδ2 T cells. Thus, Vγ9Vδ2 T cells efficiently targeted and suppressed
tumors expressing shFDPS in mouse xenotransplant models. This proof-of-concept study demonstrates the potential for suppression of genetically modified
tumors by human Vγ9Vδ2 T cells and indicates that co-expression of
cytokines may boost the anti-
tumor effect.